Insulina: Esquema de dosagem e efeitos adversos

Most patients receive a mixture of long-acting and short-acting insulin analogs through daily injections. Long-acting formulations account for 40-50% of total daily dose, providing basal coverage, while short-acting insulin covers premeal needs. A common example is a single daily injection of long-acting glargine combined with three premeal short-acting insulin injections to achieve euglycemia.

The average daily insulin dose for type 1 diabetes patients is typically 0.5-0.7 units per kilogram of body weight. However, obese patients and pubertal adolescents may require higher doses due to insulin resistance. Dose adjustments should be guided by self-monitoring of glucose and A1c measurements to achieve optimal glycemic control.

Hypoglycemia is abnormally low blood sugar, the most common adverse effect of insulin treatment. Severe hypoglycemia can cause brain damage or cardiac arrest. Glucose self-monitoring and regular A1c tests are essential to detect and prevent dangerously low glucose levels while maintaining therapeutic benefits of insulin therapy.

Repeated injections at the same site significantly enlarge subcutaneous fat depots due to insulin's lipogenic action, causing lipohypertrophy. Conversely, older insulin preparations caused lipoatrophy, or atrophy of subcutaneous fat at injection sites. Rotating injection sites helps prevent these localized fat changes and ensures consistent insulin absorption.

Mealtime insulin dose should mirror anticipated carbohydrate intake to maintain glycemic control. A supplemental scale of short-acting insulin can be added for blood glucose correction based on actual food consumption. This flexible approach, especially postprandial injection based on real intake, enables smoother glycemic control in patients with varying meal patterns.

While hypoglycemia is the most common adverse effect, rare allergic reactions to recombinant human insulin occur in some patients. Insulin treatment is also linked with modest weight gain. These rare effects must be weighed against the significant benefits of normalizing glucose control and preventing long-term diabetes complications.

Intensive regimens use long-acting insulin for basal coverage plus multiple premeal short-acting injections daily. Less intensive regimens use twice-daily intermediate-acting NPH insulin for basal coverage with regular short-acting insulin before three meals. Achieving euglycemia often requires more complex regimens, guided by therapeutic endpoints and glucose self-monitoring.